‘Nightmare bacteria’ are trying to spread in the U.S.
“Nightmare bacteria” with the power to resist most antibiotics are popping up across the U.S., but new, aggressive policies can help stop them from spreading, federal health officials said Tuesday. A new program for testing suspect bacteria turned up unusual antibiotic-resistance genes 221 times in 2017, the Centers for Disease Control and Prevention reported. And 11 percent of people screened for these superbugs carried them, even though they had no symptoms, the CDC said. “CDC’s study found several dangerous pathogens, hiding in plain sight, that can cause infections that are difficult or impossible to treat,” said the CDC’s Dr. Anne Schuchat. “While they are appearing all over the place, an aggressive approach can snuff them out.”
Antibiotic-resistant germs kill more than 23,000 Americans a year. They evolve quickly, developing mutations that let them evade the effects of antibiotics. If they are not stopped fast, they spread. Worse, the antibiotic-resistant DNA can be carried in little cassettes of genetic material called plasmids that bacteria can slip in their entirety to one another and to other species of bacteria. It’s already happened several times in the U.S. — and when one superbug gives new powers to a different superbug, the result can be an infection that is impossible to treat. “Once antibiotic resistance spreads, it is harder to control—like a wildfire,” the CDC said in a statement.
The World Health Organization has labeled antibiotic resistance a “fundamental threat” to humanity. The CDC tried out a new system aimed at quickly identifying these superbugs. They’ve helped staff up state health departments and labs to speedily test samples so that hospitals, clinics and other facilities can rapidly isolate patients infected with them. “We were able to put 500 additional staff across the country to help with this,” Schuchat told NBC News.
SAL200 to Change the Paradigm of Antibacterial Agent
The ‘inhibitor’ type of antibacterial agents that have been used for almost a century seem to no longer work against bacteria due to prevalence of antibiotic resistances. Therefore, iNtRON is shifting a paradigm of antibacterial agents from ‘inhibitors’ to ‘endolysins’, that could target specific structures of bacteria and kill them upon their contact. Followed by the leading pipeline, SAL200 for the treatment of MRSA, variety pipelines for other serious bacteria are ready to start their clinical trials in multinational countries including Korea and U.S.
it is iNtRON.